24小时热门版块排行榜    

查看: 356  |  回复: 1

abcd888898

银虫 (正式写手)

[交流] Bydureon™ Receives Marketing Authorization in Europe 已有1人参与

INDIANAPOLIS, SAN DIEGO and WALTHAM, Mass., June 21, 2011 /PRNewswire via COMTEX/ -- Eli Lilly and Company (NYSE: LLY), together with Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes, Inc. (Nasdaq: ALKS), announced today that the European Commission has granted marketing authorization to BYDUREON(TM) (exenatide 2 mg powder and solvent for prolonged release suspension for injection).


BYDUREON, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the first once-weekly treatment for type 2 diabetes. It delivers glycemic control in a single weekly dose and is indicated for the treatment of type 2 diabetes in adult patients in combination with metformin, a sulfonylurea, a thiazolidinedione, metformin plus a sulfonylurea or metformin plus a thiazolidinedione.
回复此楼
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖

sahaiqiqi

金虫 (小有名气)


全是英文
2楼2011-06-24 20:30:33
已阅   回复此楼   关注TA 给TA发消息 送TA红花 TA的回帖
相关版块跳转 我要订阅楼主 abcd888898 的主题更新
普通表情 高级回复 (可上传附件)
信息提示
请填处理意见